RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice
about
Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT miceTargeted DNA mutagenesis for the cure of chronic viral infectionsAnimal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectivesT-cell therapies for HIVCombinatorial RNA-based gene therapy for the treatment of HIV/AIDSNovel approaches to inhibit HIV entryNew generation humanized mice for virus research: comparative aspects and future prospectsHematopoietic-stem-cell-based gene therapy for HIV diseaseAchieving HIV-1 Control through RNA-Directed Gene RegulationCurrent prospects for RNA interference-based therapiesCell delivery of therapeutic nanoparticlesRectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized miceIn vivo analysis of highly conserved Nef activities in HIV-1 replication and pathogenesis.Controlling the HIV/AIDS epidemic: current status and global challengesA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Molecular and Cellular Therapies: New challenges and opportunities.RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein.Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation.Riding in silence: a little snowboarding, a lot of small RNAs.Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.Chemokine receptor 5 knockout strategies.Stem cell-based anti-HIV gene therapy.Mice with human immune system components as in vivo models for infections with human pathogens.Ex vivo gene therapy for HIV-1 treatment.One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidatesAnti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cellsThe utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment.Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized miceRNA interference approaches for treatment of HIV-1 infectionGeneration of HIV latency in humanized BLT mice.Harnessing RNAi nanomedicine for precision therapyIn vivo analysis of Nef's role in HIV-1 replication, systemic T cell activation and CD4(+) T cell loss.Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment.Nanotechnology and the treatment of HIV infection.BLT humanized mice as a small animal model of HIV infection.Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells.Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes.Progress on RNAi-based molecular medicines.Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems
P2860
Q21133769-E964AA6D-2BD1-40EB-A3BE-9E521E5C7C8BQ24620150-82E56E39-FE25-44B3-B34C-ECD89DEEFC9BQ26777022-883861EC-AD6D-4440-85CF-CA3B046F132DQ26859021-94667A05-0DC9-4A26-BD1F-428A41CFF465Q26866079-1C589471-2D66-4C82-A535-13F4ACECC8EAQ26866145-0B28035F-C28D-4063-B3F1-6892D2737DA3Q27013957-A7F9FAF8-2D1A-42EC-B18C-F3EF4CFBDF23Q27014786-FA8497A9-571A-451A-AE3F-275C40343AB4Q27023434-49160C1A-D74D-42B6-B544-150E128DCDEDQ28080090-E82A9356-A9CA-4F49-BEB8-828E2BB129D1Q28235733-18F3D3E2-06F6-4D4D-B086-B962458236FBQ28385606-5925AD91-0C28-4723-A4AC-B5D0169F890CQ28488527-2434A415-BCF1-4EE7-A6C9-F400FE6C0FBAQ30009533-EB1BBEBF-B41C-4A6F-A408-AE0F9B0D84EAQ30420558-B685CD57-9B71-49A8-BD11-A595838D4D7CQ30431343-AE681C6D-8172-4562-A75F-54E6ED0D737AQ30488022-86B236B9-3451-4ACD-ACE1-47E835269A3FQ33565464-6E53A1F7-8932-4768-B806-1903F627140EQ33687594-955012EE-48DD-454E-9826-51B9F25D9C31Q33777250-4DE72AE0-2977-4A46-962F-341D8C03A75DQ34474320-83D53DD1-DD17-4ED1-A871-EA155F221B1AQ34734219-E7E47649-52A2-420D-9993-6AA8C03644DDQ34769333-030A3040-0D77-49B2-A49B-11BBA4950FF7Q34920166-3762497A-1D1A-4139-93D0-AD497E728892Q34982851-75A82BE5-63D5-4863-B67F-35BB4CB5BD2EQ35140303-8894F283-7623-4027-9A08-D7D70DA0881DQ35144394-E56A8F71-1275-4E4D-B475-17573E6664F1Q35206268-8917836D-38D4-4094-B68A-588CD6D9667BQ35623481-06E1759B-6C56-4FF1-9BDF-D326BF283977Q35652119-85E7AFD9-476B-4AD5-8B2F-638DE7311000Q35666126-96FF00C3-AFEB-4953-A681-FA7D2F6C6837Q35673875-902CA47F-1F0A-43F2-9505-E0CE157947EBQ35848314-788C6132-2BAB-443B-8520-BC5732F39157Q35876209-E219AA34-8DC0-4D59-9674-8E73B0C7EE4CQ35943647-4CC1C085-496E-4185-A4D5-FD358D8D1D61Q35998374-2E4C0492-45B6-4F53-9385-C0E2C99EA603Q36053809-1D00DF2E-CCAA-40E5-A394-986A6C752C12Q36112824-036A0D7E-8E4B-484E-BFB1-6ED6BE3C9E30Q36161380-1CD76160-01BB-4562-B075-2D179C1E73CFQ36341433-F4B9D65C-A293-42A8-ABC0-13D350BB42AD
P2860
RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice
@ast
RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice
@en
type
label
RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice
@ast
RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice
@en
prefLabel
RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice
@ast
RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice
@en
P2093
P2860
P356
P1433
P1476
RNAi-mediated CCR5 silencing b ...... ents HIV infection in BLT mice
@en
P2093
Deshratan Asthana
Huaquan Wu
Katsuyoshi Habiro
Motomu Shimaoka
N Manjunath
Premlata Shankar
Priti Kumar
Sandesh Subramanya
Sang-Soo Kim
Yong-Guang Yang
P2860
P304
P356
10.1038/MT.2009.271
P50
P577
2009-12-08T00:00:00Z